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Ophthalmic Images buckling surgery. Visually acuity was maintained at 20/30 and retina was attached at 6-month follow-up.
CRM is rare congenital anomaly and consists of aberrant branch of a retinal vessel crossing the macula and horizontal raphe. [1] Commonly, CRM is a vein, but it may arise from an artery as well and is uusually asymptomatic. [1] Visual loss in patients with CRM has been attributed to serous detachment, [2] macro aneurysm, [3] branch retinal artery occlusion, [4] macular haemorrhage, vitreous haemorrhage, [5] foveal cyst, or mere presence of blood vessel. [1] FFA in CRM usually reveals early filling and delayed emptying and may be associated with dilated capillary bed surrounding the vessels. [6] CRM has never been reported in patient with RRD. The association of the two appears to be coincidental though.
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Nil. maculopathy bilaterally with significant outer retinal segment loss. Although retinal toxicity from hydroxychloroquine is rare, vision loss due to maculopathy is often irreversible and can be progressive. Despite the patient's daily dose of the recommended <5 mg/kg, her use of the medication for 10 years, coupled with a cumulative dose of 1460 g, increased her risk for hydroxychloroquine-related toxicity. Recommendation for immediate cessation of the hydroxychloroquine was communicated to the patient's rheumatologist. American Academy of Ophthalmology recommends baseline and annual
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Combined central retinal vein occlusion and branch retinal artery occlusion
A 66-years-old female was diagnosed to have combined central retinal vein occlusion (CRVO) and branch retinal artery occlusion (BRAO). Colour fundus photograph [ Fig. 1a] showing multiple haemorrhages and pale ischaemic area superiorly (black arrow). In Fig. 1b, fundus fluorescein angiography (FFA) shows delayed arterial filling and prolonged arteriovenous transit time. Multicolour imaging highlights the area of ischaemia (black arrow) and serous fluid in macular area as dark green as shown in Fig. 1c. In Fig. 1d and e, optical coherence tomography shows hyper-reflectivity of inner retinal layers (red arrow) and serous detachment (star), respectively.
Combined CRVO and BRAO is uncommon and the arterial occlusion is often missed. [1, 2] Echocardiography, carotid Doppler ultrasound, and magnetic resonance imaging brain should be added whenever investigating a combined occlusion. [3] Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
